Treatment of Liver Metastases With Focused Ultrasound and Microbubbles in Patients With Colorectal Cancer Receiving Chemotherapy

• Published in: Ultrasound in medicine & biology Vol. 49; no. 9; pp. 2081 - 2088
• Main Authors: Haram, Margrete, Hansen, Rune, Bouget, David, Myhre, Ola Finneng, Davies, Catharina de Lange, Hofsli, Eva
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.09.2023
• Subjects: Blood-Brain Barrier; Chemotherapy; Clinical trial; Colorectal cancer; Colorectal Neoplasms; Drug delivery; Drug Delivery Systems - methods; FOLFIRI; FOLFOXIRI; Humans; Liver metastases; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - drug therapy; Microbubbles; Sonopermeation; Ultrasound; Liver metastases; Chemotherapy; FOLFOXIRI; Sonopermeation; Colorectal cancer; Microbubbles; Clinical trial; Drug delivery; Ultrasound; FOLFIRI
• ISSN: 0301-5629; 1879-291X
• DOI: 10.1016/j.ultrasmedbio.2023.05.013

Pre-clinical trials have obtained promising results that focused ultrasound (FUS) combined with microbubbles (MBs) increases tumor uptake and the therapeutic effect of drugs. The aims of the study described here were to investigate whether FUS and MBs could improve the effect of chemotherapy in patients with liver metastases from colorectal cancer and to investigate the safety and feasibility of using FUS + MBs. We included 17 patients with liver metastases from colorectal cancer, selected two lesions in each patient's liver and randomized the lesions for, respectively, treatment with FUS + MBs or control. After chemotherapy (FOLFIRI or FOLFOXIRI), the lesions were treated with FUS (frequency = 1.67 MHz, mechanical index = 0.5, pulse repetition frequency = 0.33 Hz, 33 oscillations, duty cycle = 0.2%–0.4% and MBs (SonoVue) for 35 min). Nine boluses of MBs were injected intravenously at 3.5 min intervals. Patients were scheduled for four cycles of treatment. Changes in the size of metastases were determined from computed tomography images. Treatment with FUS + MBs is safe at the settings used. There was considerable variation in treatment response between lesions and mixed response between lesions receiving only chemotherapy. There is a tendency toward larger-volume reduction in lesions treated with FUS + MBs compared with control lesions, but a mixed response to chemotherapy and lesion heterogeneity make it difficult to interpret the results. The combination of FUS and MBs is a safe, feasible and available strategy for improving the effect of chemotherapy in cancer patients. Therapeutic effect was not demonstrated in this trial. Multicenter trials with standardized protocols should be performed.